SCHEMBL15055048

SCHEMBL15055048

COC(=O)c1ccc(NS(=O)(=O)c2cnc(Cl)c(-c3cccc(N)c3)c2)cc1O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 4/20 0.43
▸ GAA P10253 3/20 0.42
▸ USP28 Q96RU2 1/20 0.41
▸ FABP4 P15090 1/20 0.41
▸ FABP5 Q01469 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ PLAU P00749 1/20 0.40
▸ LMNA P02545 4/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ PIK3CD O00329 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37
▸ PIK3CG P48736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9996842 0.90 PFKFB3 (0.53) PFKFB3GAAUSP28FABP4FABP5
SCHEMBL15055354 0.89 PFKFB3 (0.51) PFKFB3GAAALDH1A1LMNAMAPK1
SCHEMBL15055045 0.83 SIRT6 (0.43) PFKFB3GAAFABP4FABP5ALDH1A1
SCHEMBL16408071 0.82 PFKFB3 (0.52) PFKFB3GAAALDH1A1PLAULMNA
SCHEMBL15055044 0.80 LMNA (0.44) PFKFB3GAAALDH1A1LMNAMAPK1
SCHEMBL9997499 0.80 PFKFB3 (0.55) PFKFB3ALDH1A1LMNAMCL1MAPT
SCHEMBL9997078 0.80 PFKFB3 (0.55) PFKFB3GAAFABP4FABP5ALDH1A1
SCHEMBL15055572 0.80 PFKFB3 (0.63) PFKFB3GAAUSP28FABP4FABP5
SCHEMBL15055480 0.80 ALDH1A1 (0.49) GAAALDH1A1LMNAMAPK1L3MBTL1
SCHEMBL15055006 0.79 PKM (0.44) PFKFB3GAAFABP4ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP claimed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US claimed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US claimed
CN-104168958-A Diaryl sulfonamides useful for the treatment of inflammation and cancer KANCERA AB 2014-11-26 — — CN claimed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP claimed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO claimed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US disclosed
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2018-06-19 — — US disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP disclosed
EP-2794009-B1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2017-08-30 — — EP disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 — — US disclosed
US-9718809-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer KANCERA AB (SE) 2017-08-01 — — US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US disclosed
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2016-08-04 — — US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US disclosed
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2015-01-22 — — US disclosed
CN-104168958-A Diaryl sulfonamides useful for the treatment of inflammation and cancer KANCERA AB 2014-11-26 — — CN disclosed
EP-2794009-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER Kancera AB (SE) 2014-10-29 — — EP disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO disclosed
WO-2013093095-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025068-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 909/4885GAA 3378/4885USP28 2827/4885
US-20160221938-A1 BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER NFKBIA, IL6, LITAF PFKFB3 988/4885GAA 3393/4885USP28 2875/4885
US-10000449-B2 Bisarylsulfonamides useful in the treatment of inflammation and cancer NFKBIA, IL6, LITAF PFKFB3 988/4885GAA 3393/4885USP28 2875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback